GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Sophia Genetics SA (NAS:SOPH) » Definitions » Loans Receivable

SOPH (Sophia Genetics) Loans Receivable : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sophia Genetics Loans Receivable?

Sophia Genetics's Loans Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.


Sophia Genetics Loans Receivable Historical Data

The historical data trend for Sophia Genetics's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophia Genetics Loans Receivable Chart

Sophia Genetics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial - - - - -

Sophia Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sophia Genetics Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Sophia Genetics Loans Receivable Related Terms

Thank you for viewing the detailed overview of Sophia Genetics's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Sophia Genetics Business Description

Traded in Other Exchanges
Address
La Pièce 12, Rolle, CHE, CH-1180
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.